 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The latest Phase 1 trial results of Agenus' botensilimab and balstilimab (BOT/BAL) combination therapy for metastatic CRC showcase promising clinical activity.

 Latest Ratings for AGEN...

Small-Cap Cancer Drug Developer Agenus' Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns Loom

Agenus Inc. (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced updated results from its Phase 1 clinical trial of BOT/BAL...

Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer

Down 75%. Is Agenus Stock a Buy on the Dip...

Down 75%. Is Agenus Stock a Buy on the Dip?

Agenus Inc. (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced its stockholders have approved a one-for-twenty reverse stock...

Agenus Announces Reverse Stock Split of Common Stock

Agenus Inc. ( NASDAQ:AGEN ) shareholders that were waiting for something to happen have been dealt a blow with a 25...

Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet

StockNews.com upgraded shares of Agenus (NASDAQ:AGEN  Free Report) from a sell rating to a hold rating in a research report released on Sunday morning. Several other analysts have also issued...

Agenus (NASDAQ:AGEN) Upgraded to Hold at StockNews.com

Agenus (NASDAQ:AGEN  Free Report) had its price objective cut by B. Riley from $6.00 to $5.00 in a report published on Monday morning, Benzinga reports. They currently have a buy rating on the...

Agenus (NASDAQ:AGEN) PT Lowered to $5.00 at B. Riley

Q4 2023 Agenus Inc Earnings Call and Corporate Update Transcript

Fast Track Designation for BOT/BAL in Colorectal Cancer and $25 Million Milestone Payment Highlight ProgressRelated Stocks: AGEN...

Agenus Inc (AGEN) Reports Full Year and Q4 2023 Financial Results, Advances in Oncology Pipeline

Agenus GAAP EPS of -$0.13 misses by $0.08, revenue of $83.8M beats by $36.75M...

Agenus GAAP EPS of -$0.13 misses by $0.08, revenue of $83.8M beats by $36.75M

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Volume (M)	129.00
52-Wk High	$42.60
52-Wk Low	$4.78

AGEN Agenus Inc

About

Feed

News

Sentiment

Earnings

Fundamentals